Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Commercial Ofc Imm Med | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 221,278 |
Ending reported balance
After 2026-06-29 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-06-26 · Exercise / conversion · Acquired 11,034 · Balance 283,785 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Row 2 · 2026-06-26 · Sale · Disposed 11,034 · Balance 272,751 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-06-29 · Exercise / conversion · Acquired 1,837 · Balance 274,588 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Row 4 · 2026-06-29 · Exercise / conversion · Acquired 24,944 · Balance 299,532 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Row 5 · 2026-06-29 · Exercise / conversion · Acquired 24,944 · Balance 324,476 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Row 6 · 2026-06-29 · Exercise / conversion · Acquired 51,570 · Balance 376,046 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Row 7 · 2026-06-29 · Sale · Disposed 154,768 · Balance 221,278 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 1,837 |
Reported balance
After 2026-06-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-26 · Exercise / conversion · Disposed 11,034 · Balance 1,837 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F4: The option was fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 0 |
Reported balance
After 2026-06-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-06-29 · Exercise / conversion · Disposed 1,837 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F4: The option was fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2033-03-06 | Direct | 37,416 |
Reported balance
After 2026-06-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-29 · Exercise / conversion · Disposed 24,944 · Balance 37,416 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F5: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2034-03-04 | Direct | 87,303 |
Reported balance
After 2026-06-29 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-29 · Exercise / conversion · Disposed 24,944 · Balance 87,303 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F6: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.12 · Expires 2035-03-04 | Direct | 113,457 |
Reported balance
After 2026-06-29 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-06-29 · Exercise / conversion · Disposed 51,570 · Balance 113,457 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F7: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025.
F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The option was fully vested and exercisable.
F5: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F6: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F7: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 51,570 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · derivative · entry 12 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,457 Underlying: Common Stock · 51,570 shares Expires 2035-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 24,944 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · derivative · entry 11 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,303 Underlying: Common Stock · 24,944 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 24,944 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · derivative · entry 10 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,416 Underlying: Common Stock · 24,944 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 1,837 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · derivative · entry 9 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,837 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F4 · derivative.exercise_date: The option was fully vested and exercisable. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 154,768 | $21.14 | $3,271,795.52 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · nonDerivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,278 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 51,570 | $8.12 | $418,748.40 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · nonDerivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 24,944 | $3.99 | $99,526.56 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · nonDerivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 324,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 24,944 | $8.46 | $211,026.24 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 299,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,837 | $12.14 | $22,301.18 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,034 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · derivative · entry 8 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,837 Underlying: Common Stock · 11,034 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F4 · derivative.exercise_date: The option was fully vested and exercisable. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 11,034 | $21.00 | $231,714.00 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 272,751 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,034 | $12.14 | $133,952.76 |
DisclosureSEC source: 0001780854-26-000008 · form4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:55 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 63,103 | $13.17 | $831,066.51 |
DisclosureSEC source: 0001780854-26-000004 · form4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,751 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 39,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001780854-26-000002 · form4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,854 Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 4,157 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780854-25-000003 · primary_doc.xml · derivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,247 Underlying: Common Stock · 4,157 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 4,157 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780854-25-000003 · primary_doc.xml · derivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,360 Underlying: Common Stock · 4,157 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 4,290 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780854-25-000003 · primary_doc.xml · derivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,871 Underlying: Common Stock · 4,290 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 12,604 | $16.85 | $212,377.40 |
DisclosureSEC source: 0001780854-25-000003 · primary_doc.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,791 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.66 to $16.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 4,157 | $3.99 | $16,586.43 |
DisclosureSEC source: 0001780854-25-000003 · primary_doc.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 4,157 | $8.46 | $35,168.22 |
DisclosureSEC source: 0001780854-25-000003 · primary_doc.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 4,290 | $12.14 | $52,080.60 |
DisclosureSEC source: 0001780854-25-000003 · primary_doc.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 83,145 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 18 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,404 Underlying: Common Stock · 83,145 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F8 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 119,809 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 17 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,161 Underlying: Common Stock · 119,809 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 34,375 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 16 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,375 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 49,480 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 15 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,480 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 20,834 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 14 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,834 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 834 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 13 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 834 shares Expires 2027-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 308,477 | $16.91 | $5,216,346.07 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 10 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,791 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F10 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 83,145 | $3.99 | $331,748.55 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 9 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 119,809 | $12.14 | $1,454,481.26 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 8 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 522,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 34,375 | $7.27 | $249,906.25 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 402,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 49,480 | $6.55 | $324,094.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 367,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 20,834 | $6.55 | $136,462.70 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 318,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 834 | $6.27 | $5,229.18 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 297,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 68,961 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 12 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,970 Underlying: Common Stock · 68,961 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 133,032 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · derivative · entry 11 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,517 Underlying: Common Stock · 133,032 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 6, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 297,925 | $16.54 | $4,927,679.50 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,791 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F9 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 68,961 | $12.14 | $837,186.54 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 594,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 02:39 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 133,032 | $8.46 | $1,125,450.72 |
DisclosureSEC source: 0001780854-25-000002 · primary_doc.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 525,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,065 | $6.99 | $21,424.35 |
DisclosureSEC source: 0001062993-25-004815 · form4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,723 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 41,600 | $6.98 | $290,368.00 |
DisclosureSEC source: 0001062993-25-004815 · form4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,788 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 165,027 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001062993-25-004815 · form4.xml · derivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,027 Underlying: Common Stock · 165,027 shares Expires 2035-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 109,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004815 · form4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,388 Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 18,644 | $3.44 | $64,135.36 |
DisclosureSEC source: 0001062993-24-005762 · form4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,415 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,746 | $3.43 | $36,858.78 |
DisclosureSEC source: 0001062993-24-005762 · form4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,059 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 199,549 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001062993-24-005762 · form4.xml · derivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,549 Underlying: Common Stock · 199,549 shares Expires 2034-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 132,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005762 · form4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,805 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:02 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 199,549 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006325 · form4.xml · derivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,549 Underlying: Common Stock · 199,549 shares Expires 2033-03-06 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:02 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 11,749 | $8.57 | $100,688.93 |
DisclosureSEC source: 0001062993-23-006325 · form4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,826 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:02 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 132,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006325 · form4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,575 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.